BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Serenex 

323 Foster Street

Durham  North Carolina  27701  U.S.A.
Phone: 919-281-6001 or 888-733-0033 Fax: 919-281-6050


SEARCH JOBS


Industry
Biotechnology






 Company News
NC Judge Awards $57 Million to Durham Drug Company, Serenex 9/5/2008 7:18:43 AM    More...
Coserics Announces Company Formation Including Spin-Out of Phase 2 Clinical Asset From Serenex 4/17/2008 11:02:19 AM    More...
Serenex Announces Collaboration With National Cancer Institute to Initiate Clinical Trial With Serenex's Proprietary Small Molecule HSP90 Inhibitor, SNX-5422 2/27/2008 10:11:05 AM    More...
Serenex Announces Collaboration With National Cancer Institute to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Lung Cancer 1/24/2008 9:44:50 AM    More...
Multiple Myeloma Research Foundation (MMRF) Grants $3.5 Million in Biotech Investment Awards 1/23/2008 10:59:39 AM    More...
Serenex and CHDI, Inc. Form Agreement to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Huntington's Disease 1/17/2008 9:24:08 AM    More...
Serenex Announces Initiation of Second Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422 12/4/2007 12:42:06 PM    More...
Serenex to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference 10/23/2007 8:22:00 AM    More...
Serenex to Present at Biotechnology Industry Organization (BIO) Investor Forum 2007 10/9/2007 8:38:46 AM    More...
Serenex Announces Initiation of Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422 5/31/2007 10:02:48 AM    More...
1234

//-->